Ralph Niven, Chief Scientific Officer at Aerovate Therapeutics, Inc. (AVTE), sold 2,250 shares at $21.18 ($48K) on 2022-08-18, disclosed to the SEC on 2022-08-19.
Scheduled sale ($48k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| AVTE | SELL | 2023-12-07 | $75K | — | Filing → |
| AVTE | SELL | 2023-11-27 | $207K | — | Filing → |
| AVTE | SELL | 2023-07-07 | $39K | — | Filing → |